GARDASIL 9 is indicated in females aged 9 to 45 years* for the prevention of cervical, vulvar, vaginal and anal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by Human Papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (which are included in the vaccine).,GARDASIL 9 is indicated in males aged 9 to 45 years* for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions, and infection caused by Human Papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (which are included in the vaccine).,* Evidence of vaccine efficacy is based on the core efficacy population of females aged 16 to 26 years. Immunogenicity studies have been conducted to link efficacy to younger populations (females and males aged 9 to 15 years). Immunogenicity studies of GARDASIL 9 have been conducted relating to females over 26 years of age (see section 5.1 CLINICAL TRIALS for GARDASIL 9).
How to take it
The way to take this medicine is: Intramuscular.
This medicine is given through a needle inserted into the muscle beneath the skin.
Store at 2 to 8 degrees Celsius
Protect from Light
Refrigerate
Do not Freeze
Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
White cloudy liquid. (Prior to agitation, may appear as a clear liquid with a white precipitate.)
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Schedule 4 : Prescription Only Medicine.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
GARDASIL 9 is indicated in females aged 9 to 45 years* for the prevention of cervical, vulvar, vaginal and anal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by Human Papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (which are included in the vaccine).,GARDASIL 9 is indicated in males aged 9 to 45 years* for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions, and infection caused by Human Papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (which are included in the vaccine).,* Evidence of vaccine efficacy is based on the core efficacy population of females aged 16 to 26 years. Immunogenicity studies have been conducted to link efficacy to younger populations (females and males aged 9 to 15 years). Immunogenicity studies of GARDASIL 9 have been conducted relating to females over 26 years of age (see section 5.1 CLINICAL TRIALS for GARDASIL 9).
How to take it
The way to take this medicine is: Intramuscular.
This medicine is given through a needle inserted into the muscle beneath the skin.
Store at 2 to 8 degrees Celsius
Protect from Light
Refrigerate
Do not Freeze
Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
White cloudy liquid. (Prior to agitation, may appear as a clear liquid with a white precipitate.)
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Schedule 4 : Prescription Only Medicine.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
GARDASIL 9 is indicated in females aged 9 to 45 years* for the prevention of cervical, vulvar, vaginal and anal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by Human Papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (which are included in the vaccine).,GARDASIL 9 is indicated in males aged 9 to 45 years* for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions, and infection caused by Human Papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (which are included in the vaccine).,* Evidence of vaccine efficacy is based on the core efficacy population of females aged 16 to 26 years. Immunogenicity studies have been conducted to link efficacy to younger populations (females and males aged 9 to 15 years). Immunogenicity studies of GARDASIL 9 have been conducted relating to females over 26 years of age (see section 5.1 CLINICAL TRIALS for GARDASIL 9).
How to take it
The way to take this medicine is: Intramuscular.
This medicine is given through a needle inserted into the muscle beneath the skin.
Store at 2 to 8 degrees Celsius
Protect from Light
Refrigerate
Do not Freeze
Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
White cloudy liquid. (Prior to agitation, may appear as a clear liquid with a white precipitate.)
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Schedule 4 : Prescription Only Medicine.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
GARDASIL 9 is indicated in females aged 9 to 45 years* for the prevention of cervical, vulvar, vaginal and anal cancer, precancerous or dysplastic lesions, genital warts, and infection caused by Human Papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (which are included in the vaccine).,GARDASIL 9 is indicated in males aged 9 to 45 years* for the prevention of anal cancer, precancerous or dysplastic lesions, external genital lesions, and infection caused by Human Papillomavirus (HPV) types 6, 11, 16, 18, 31, 33, 45, 52 and 58 (which are included in the vaccine).,* Evidence of vaccine efficacy is based on the core efficacy population of females aged 16 to 26 years. Immunogenicity studies have been conducted to link efficacy to younger populations (females and males aged 9 to 15 years). Immunogenicity studies of GARDASIL 9 have been conducted relating to females over 26 years of age (see section 5.1 CLINICAL TRIALS for GARDASIL 9).
How to take it
The way to take this medicine is: Intramuscular.
This medicine is given through a needle inserted into the muscle beneath the skin.
Store at 2 to 8 degrees Celsius
Protect from Light
Refrigerate
Do not Freeze
Shelf lifetime is 36 Months.
You should seek medical advice in relation to medicines and use only as directed by a healthcare professional.
Always read the label. If symptoms persist see your healthcare professional.
Visual appearance
White cloudy liquid. (Prior to agitation, may appear as a clear liquid with a white precipitate.)
Do I need a prescription?
This medicine is available from a pharmacist and requires a prescription. It is
Schedule 4 : Prescription Only Medicine.
You should seek advice from your doctor or pharmacist about taking this medicine. They can help you balance the risks and the benefits of this medicine during pregnancy.
Government Accredited with over 140 information partners
We are a government-funded service, providing quality, approved health information and advice
Healthdirect Australia acknowledges the Traditional Owners of Country throughout Australia and their continuing
connection to land, sea and community. We pay our respects to the Traditional Owners and to Elders both past and
present.